In diabetic autonomic neuropathy, low plasma noradrenaline is a late sign, and while cardiovascular responses to catecholamines are enhanced, there is no generalized up-regulation of adrenoceptors on circulating blood cells.
Answers are grounded in this paper and cite their sources.
Low noradrenaline marks late-stage diabetic autonomic neuropathy; leaves open mechanisms of enhanced catecholamine responses without blood-cell adrenoceptor changes.
In diabetic patients with autonomic neuropathy plasma noradrenaline concentration, used as an index of sympathetic nervous activity, is low. This decrease is, however, only found in patients with a long duration of diabetes with clinically severe autonomic neuropathy. This apparent insensitivity of plasma catecholamine measurements is not due to changes in the clearance of catecholamines in diabetic autonomic neuropathy. The physiological responses to infused adrenaline and to noradrenaline are enhanced, for noradrenaline mainly cardiovascular responses. Adrenoceptors (alpha and beta adrenoceptors) are not altered in circulating blood cells in diabetic autonomic neuropathy. Thus, a generalized up-regulation of adrenoceptors does not occur in diabetic autonomic neuropathy.
No takes yet. Share an insight, caveat, or question.
J. Hilsted (1995) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: